We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+42.04%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$128M
Cap. Flow
-$241M
Cap. Flow %
-12%
Top 10 Hldgs %
57.08%
Holding
77
New
4
Increased
7
Reduced
4
Closed
25

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$34.9M
2
GPCR icon
Structure Therapeutics
GPCR
+$22.9M
3
ARVN icon
Arvinas
ARVN
+$14.2M
4
TNGX icon
Tango Therapeutics
TNGX
+$9.33M
5
IMVT icon
Immunovant
IMVT
+$9.2M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$38.2M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$36.5M
3
VTYX
Ventyx Biosciences
VTYX
+$29.5M
4
FOLD
Amicus Therapeutics
FOLD
+$28.3M
5
EXEL icon
Exelixis
EXEL
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$188M 9.37%
3,201,440
– –
CYTK icon
2
Cytokinetics
CYTK
$10.5B
$175M 8.74%
2,100,000
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$125M 6.22%
3,421,541
– –
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$123M 6.12%
4,279,464
-404,800
-9% -$9.73M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$103M 5.15%
1,726,000
– –
ONC
6
BeOne Medicines Ltd
ONC
$32.8B
$90.2M 4.49%
500,000
– –
TYRA icon
7
Tyra Biosciences
TYRA
$1.9B
$89.3M 4.45%
6,448,359
– –
IMGN
8
DELISTED
Immunogen Inc
IMGN
$87.8M 4.38%
2,961,000
– –
NUVL
9
DELISTED
Nuvalent
NUVL
$82.4M 4.11%
1,120,192
-90,000
-7% -$5.57M
TNGX icon
10
Tango Therapeutics
TNGX
$4.43B
$81.2M 4.05%
8,198,642
+1,075,000
+15% +$9.33M
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$79.1M 3.94%
250,000
– –
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.42B
$78.4M 3.91%
2,202,812
– –
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.57B
$62.7M 3.12%
650,000
+50,000
+8% +$4.8M
ARGX icon
14
argenx
ARGX
$53.4B
$60.9M 3.03%
160,000
+75,000
+88% +$34.9M
MRUS
15
DELISTED
Merus
MRUS
$52.3M 2.6%
1,900,000
– –
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$340M
$43.9M 2.19%
1,466,051
– –
IMVT icon
17
Immunovant
IMVT
$7.93B
$42.1M 2.1%
1,000,000
+250,000
+33% +$9.2M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$39.2M 1.95%
1,676,733
– –
LEGN icon
19
Legend Biotech
LEGN
$3.59B
$36.1M 1.8%
600,000
– –
AXSM icon
20
Axsome Therapeutics
AXSM
$11.2B
$31.8M 1.59%
400,000
– –
RCUS icon
21
Arcus Biosciences
RCUS
$3.55B
$30.6M 1.53%
1,602,200
– –
ANAB icon
22
AnaptysBio
ANAB
$1.58B
$27.8M 1.39%
1,300,000
– –
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.06B
$27.6M 1.38%
600,000
– –
ARVN icon
24
Arvinas
ARVN
$518M
$25.1M 1.25%
+608,614
New +$14.2M
PRTA icon
25
Prothena Corp
PRTA
$425M
$24.2M 1.2%
665,000
+40,000
+6% +$1.54M
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Boxer Capital held 77 positions worth $2.01B, up 6.8% from $1.88B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Boxer Capital withdrew a net $241M in Q4 2023, closing 25 positions and reducing 4 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $38.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Structure Therapeutics worth $16.3M.

  • Boxer Capital's largest Q4 2023 buy was Structure Therapeutics: 400,000 shares worth $16.3M.
  • Boxer Capital added most to argenx in Q4 2023, an estimated $34.9M increase.
  • Boxer Capital's biggest Q4 2023 reduction was Iovance Biotherapeutics, cutting an estimated $12.1M.
  • Boxer Capital fully exited Amylyx Pharmaceuticals in Q4 2023, selling an estimated $38.2M.
  • Boxer Capital's ten largest holdings make up 57% of its $2.01B portfolio in Q4 2023.
  • Boxer Capital opened 4 new positions and closed 25 in Q4 2023.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $2.01B.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.